Business Overview: Oruka Therapeutics, Inc. (NASDAQ: ORKA)

---

Executive Summary

Oruka Therapeutics is a clinical-stage biopharmaceutical company developing long-acting monoclonal antibodies for psoriasis and other immune-mediated inflammatory diseases. Oruka was formed in early 2024 by Peter Harwin and Fairmount Funds Management, in partnership with biotech "hub" incubator Paragon Therapeutics, which licensed Oruka two clinical-stage antibody programs originally developed to compete with blockbuster IL-23 and IL-17 inhibitors. The company became public in August 2024 through a reverse merger with the shell of ARCA biopharma (ticker changed from ABIO to ORKA), a now-common structure used by Fairmount/Paragon-affiliated biotech start-ups (a playbook also used for Alumis, Spyre Therapeutics, and others) to reach the public markets quickly with cash already in hand. Oruka is headquartered in Menlo Park, California.

Oruka has no approved products, no commercial organization, and no revenue — it is a pure-play, pipeline-stage drug developer. What distinguishes it from the typical small, cash-strapped clinical biotech is its balance sheet: following a series of large private placements and a public offering, Oruka held roughly $1.1 billion in cash, cash equivalents, and marketable securities as of mid-2026, against a quarterly net loss in the $40-million range — implying many years of funded runway and explicitly removing near-term financing or going-concern risk from the investment case. The company's strategy is to engineer "best-in-class" versions of already-validated drug targets (IL-23p19 and IL-17A/F) using half-life-extension technology intended to support dosing as infrequently as once or twice a year, competing on convenience and durability of response rather than on discovering a novel mechanism.

---

1. Core Business Model & How They Work

Oruka does not sell anything today. Its "business model" is the standard clinical-stage biotech value-creation loop: license or build a drug candidate, run it through clinical trials to generate human safety/efficacy data, use that data to raise capital or attract a partner/acquirer, and ultimately either (a) file for regulatory approval and commercialize the drug itself, or (b) be acquired by (or out-license to) a larger pharmaceutical company once the clinical risk has been substantially reduced. Value is created by "de-risking" — each successful trial readout should re-rate the company's value upward.

 Target biology            Clinical development          Value realization
 (validated targets:     ➡️  (Phase 1/2/3 trials,      ➡️  (BLA filing + launch,
  IL-23p19, IL-17A/F,         biomarker & efficacy          OR acquisition / licensing
  TL1A)                       readouts)                     deal with Big Pharma)
      |                            |                              |
      v                            v                              v
 Paragon Therapeutics      Capital markets fund the      Royalties/milestones owed
 licenses in antibody      trials (equity raises,        back to Paragon Therapeutics
 assets (ORKA-001,         private placements) —         on any approved product;
 ORKA-002, ORKA-004)       currently ~$1.1B in cash       Halozyme Hypercon royalty
                           funds the pipeline without     on subcutaneous formulation
                           near-term dilution risk

Because Oruka licenses rather than discovers its core antibodies, Paragon Therapeutics is owed milestone payments and royalties on each program (e.g., ~$7.0 million and ~$4.0 million in milestones expensed for the IL-23p19 and IL-17A/F programs, respectively, through year-end 2025), which is an important cost layer embedded in the model. Oruka has also licensed Halozyme's "Hypercon" half-life-extension/subcutaneous-delivery technology for ORKA-001, paying an upfront fee and owing future milestones/royalties — another layer of economics any eventual product must absorb.

---

2. Product Portfolio (Pipeline)

Oruka has no marketed products. Its entire value rests on an early-stage pipeline of monoclonal antibodies targeting inflammatory skin and immune diseases.

None of these candidates has generated pivotal (Phase 3) efficacy data or been submitted for regulatory approval, so every entry above carries the ordinary high failure rate of clinical-stage drug development.

---

3. Competitive Landscape

Oruka is attacking two of the most crowded and commercially successful drug classes in immunology — IL-23 and IL-17 inhibitors for psoriasis — where competitors are large, well-capitalized, and already generating billions of dollars in product revenue.

• Approved IL-23 inhibitors: Skyrizi (AbbVie), Tremfya (Janssen/J&J), Ilumya (Sun Pharma), Stelara (Janssen).
• Approved IL-17 inhibitors: Cosentyx (Novartis), Taltz (Eli Lilly), Bimzelx (UCB), Siliq (Ortho Dermatologics).
• Older TNF-alpha biologics: Humira (AbbVie), Enbrel (Amgen), Remicade (Janssen) — largely displaced by newer mechanisms but still prescribed.
• Oral agents: Otezla (Amgen), Sotyktu (Bristol-Myers Squibb).
• Late-stage pipeline rivals pursuing the same "better-than-approved" positioning: sonelokimab (MoonLake Immunotherapeutics), icotrokinra/JNJ-2113 (Janssen), zasocitinib (Takeda), envudeucitinib/ESK-001 (Alumis — itself a Fairmount/Paragon sister company), and AbbVie's own early-stage long-acting IL-23p19 program.

                      High durability / infrequent dosing
                                    ^
                                    |
                     ORKA-001 *  (claimed 1-2x/yr dosing)
                                    |
    Established,                  |                  Emerging,
    high-revenue  <----------------+----------------> unproven
    incumbents                     |                  challengers
   (Skyrizi,Tremfya,               |              (sonelokimab,
    Cosentyx,Taltz)                |         icotrokinra, ORKA-002)
                                    |
                                    v
                      Standard dosing frequency (q4-12 weeks)

Oruka's bet is that meaningfully less-frequent dosing (once or twice yearly vs. quarterly) is a strong enough convenience/compliance advantage to win share even against entrenched, revenue-generating incumbents — but it must first prove that efficacy and safety are non-inferior to those incumbents in head-to-head-caliber data, which it has not yet done.

---

4. Strategic Strengths & Risks

Strengths / potential moat sources:

• Exceptional balance sheet for its stage — roughly $1.1 billion in cash and marketable securities funds the pipeline deep into (and likely through) the ORKA-001 BLA filing, removing the financing/dilution overhang that plagues most clinical-stage biotechs.
• De-risked, clinically validated targets — IL-23p19 and IL-17A/F are proven mechanisms with multiple approved, high-selling drugs, which lowers (though does not eliminate) mechanistic/biological risk relative to novel-target biotechs.
• Differentiated half-life-extension engineering (YTE) and the Halozyme Hypercon license aim to create genuine product differentiation (dosing frequency) rather than relying on a "me-too" profile.
• Experienced sponsor network — Fairmount Funds Management and Paragon Therapeutics have run this incubation playbook successfully across several biotechs, giving Oruka access to experienced management and infrastructure.

Risks:

• No approved products and no revenue — the entire valuation rests on binary clinical trial readouts (first pivotal PsO data not expected until late 2026/2027) and eventual regulatory approval, which is inherently uncertain.
• Crowded, commercially mature competitive set — IL-23/IL-17 inhibitors from AbbVie, J&J, Novartis, Eli Lilly, and UCB already dominate with large prescriber bases, payer contracts, and real-world data; dosing-frequency alone may not be sufficient to displace them.
• Economics layered with royalty/milestone obligations to Paragon Therapeutics and Halozyme reduce the eventual profit pool versus a fully in-house program.
• Rising cash burn — net loss roughly doubled year-over-year in Q2 2026 (to ~$41 million) as trials scale, and further large capital commitments (e.g., Phase 3 trial starts in 2027) will continue to draw down the cash pile.
• Single-class concentration risk — the two lead assets both target inflammatory skin disease mechanisms; a class-wide safety signal or a stronger-than-expected competitor readout (e.g., from sonelokimab or icotrokinra) could damage multiple programs simultaneously.

---

5. Financial Overview

Because Oruka has no revenue or earnings, traditional profitability ratios (margin, ROIC) are not meaningful; the relevant financial question is runway (cash versus burn rate), where Oruka is unusually strong for a clinical-stage biotech.

---

6. Summary Conclusion

Oruka Therapeutics is a clinical-stage drug developer whose investment case is built entirely on the future success of two licensed-in antibodies targeting proven immunology mechanisms, engineered for much less frequent dosing than today's approved biologics. Unlike many small-cap clinical biotechs, Oruka is not financially fragile: its roughly $1.1 billion cash position, built through large private placements and a strong sponsor network (Fairmount/Paragon), funds it well past its next major catalysts without the near-term going-concern or dilution risk typical of the sector. The company's biggest forward risk is not solvency but clinical and commercial execution — it must generate pivotal-quality efficacy and safety data against mechanisms where AbbVie, Johnson & Johnson, Novartis, Eli Lilly, and UCB already sell blockbuster, well-entrenched drugs, and then prove that less-frequent dosing is a decisive enough advantage to win meaningful market share (or to make Oruka an attractive acquisition target) before its cash advantage erodes.